DuPont Unveils New Resin for Biopharmaceutical Purification

Published 44 minutes agoDD

DuPont Unveils New Resin for Biopharmaceutical Purification

DuPont has recently introduced a new resin aimed at enhancing biopharmaceutical purification, marking a significant expansion in its pharmaceutical product offerings. This development accompanies the company's efforts to increase production capacity for ion exchange resins, which are essential for the growing market demand for pharmaceutical products such as excipients and active pharmaceutical ingredients (APIs).

In a move to bolster its manufacturing capabilities, DuPont has successfully completed the initial phase of expanding its cGMP pharmaceutical production facilities in Chauny, France. This expansion includes ongoing qualifications, with future phases designed to meet the high demand for excipient and absorbent products. DuPont's ion exchange resins are integral to a wide range of pharmaceutical applications, including drug formulations and advanced drug delivery systems.

Furthermore, DuPont is committed to enhancing its regulatory resources to support the development of new applications and maintain the highest standards of product quality across different markets. This strategic initiative highlights DuPont's dedication to facilitating the growth of the pharmaceutical industry and catering to the evolving needs of its clients, as reported by sources like DuPont's website.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Affirm and KAYAK's Partnership Remains U.S.-Exclusive

Affirm and KAYAK's Partnership Remains U.S.-Exclusive

14 minutes agoAFRM

As of May 22, 2025, the partnership between Affirm and KAYAK remains distinctly American. Originally formed in January 2023, this alliance identified Affirm as the exclusive pay-over-time provider for KAYAK within the United States. The union aimed to give travelers more flexible payment options when booking trips through KAYAK. In different territories, Affirm has been expanding its reach with various partners. Notably, in June 2024, Affirm teamed up with Alterra Mountain Company in Canada, marking a significant step in their Canadian collaborations. However, there's no clear indication that Affirm and KAYAK have looked north to expand their exclusive arrangement. Despite the broader growth of Affirm in regions such as Canada, the extension of its partnership with KAYAK remains confined to the U.S. landscape. These developments underscore Affirm's strategy to selectively grow its collaborative network, as information from Reuters suggests their focus may still be aligned with the initial terms of engagement with KAYAK.

UnitedHealthcare Under Scrutiny Amid Leadership Shakeup

UnitedHealthcare Under Scrutiny Amid Leadership Shakeup

29 minutes agoUNH

UnitedHealthcare, the largest insurance provider in the United States, is facing significant pressure following a series of troubling developments. The U.S. Department of Justice has launched a criminal investigation into the company's Medicare practices, specifically targeting the billing practices of its Medicare Advantage unit. This investigation comes on the heels of UnitedHealthcare's unexpected decision to withdraw its financial outlook and the sudden departure of CEO Andrew Witty, as Reuters reported. These issues have sparked a sharp decline in UnitedHealth's stock value, with shares plummeting 14% in a single day and suffering a 46% drop year-to-date. This stark decrease has brought the company's stock to a nearly five-year low, adding fuel to investor concerns about the company's trajectory amid these challenges. Adding to the company's troubles is its high rate of claim denials, where one in three claims is dismissed—twice the industry average. The Department of Justice is also scrutinizing UnitedHealth's proposed $3.3 billion purchase of Amedisys Inc., raising antitrust concerns. Meanwhile, the tragic shooting death of CEO Brian Thompson has resulted in further political and public scrutiny, especially following revelations that the ammunition used was labeled with references tied to the insurer's controversial practices.

DuPont Unveils New Resin for Biopharmaceutical Purification

DuPont Unveils New Resin for Biopharmaceutical Purification

44 minutes agoDD

DuPont has recently introduced a new resin aimed at enhancing biopharmaceutical purification, marking a significant expansion in its pharmaceutical product offerings. This development accompanies the company's efforts to increase production capacity for ion exchange resins, which are essential for the growing market demand for pharmaceutical products such as excipients and active pharmaceutical ingredients (APIs). In a move to bolster its manufacturing capabilities, DuPont has successfully completed the initial phase of expanding its cGMP pharmaceutical production facilities in Chauny, France. This expansion includes ongoing qualifications, with future phases designed to meet the high demand for excipient and absorbent products. DuPont's ion exchange resins are integral to a wide range of pharmaceutical applications, including drug formulations and advanced drug delivery systems. Furthermore, DuPont is committed to enhancing its regulatory resources to support the development of new applications and maintain the highest standards of product quality across different markets. This strategic initiative highlights DuPont's dedication to facilitating the growth of the pharmaceutical industry and catering to the evolving needs of its clients, as reported by sources like DuPont's website.

Ralph Lauren Exceeds Expectations with Strong Q2 Results and Dividend Hike

Ralph Lauren Exceeds Expectations with Strong Q2 Results and Dividend Hike

59 minutes agoRL

Ralph Lauren Corporation has reported impressive financial outcomes for its fiscal second quarter, significantly surpassing analysts' forecasts. The company posted an adjusted earnings per share (EPS) of $2.10, beating the Zacks Consensus Estimate of $1.92. Additionally, net revenues showed a healthy year-over-year increase of 3%, totaling $1.633 billion and surpassing expectations of $1.609 billion. In addition to these positive earnings, Ralph Lauren announced an increase in its quarterly cash dividend from $0.75 to $0.825 per share. The company also demonstrated robust operating performance, with its adjusted operating margin improving by 230 basis points to 18.7% and operating profit climbing by 27%. Global performance was strong as well, with notable revenue growth in Asia and Europe, where sales surged by 15% and 16%, respectively. The direct-to-consumer segment also saw remarkable expansion, adding 1.9 million new consumers. These results reflect Ralph Lauren's strategic initiatives aimed at strengthening its financial position while responding to broader economic challenges. Reuters highlighted that the dividend increase underscores the company's commitment to maximizing shareholder value.